Michael Thomas Henderson insider trades
Michael Thomas Henderson has filed 34 Form 4s with the SEC that we hold, for Apogee Therapeutics, Inc. (APGE) (Chief Executive Officer, Director), Spyre Therapeutics, Inc. (SYRE) (Director) and ARYD (Director). Across all of them we count 0 purchases worth $0 and 55 sales worth $45.9M reported on Form 4. In the last 12 months: 0 purchases ($0) and 38 sales ($36.3M). The largest single trade was a sale of 80,000 shares of Apogee Therapeutics, Inc. worth $10.6M, dated 2026-06-22. The first filing on our record is dated 2023-12-20 and the latest 2026-09-03.
Apogee Therapeutics, Inc. (APGE)
Chief Executive Officer, Director · 26 filings · 50 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2024-07-05 | S, sale reported on Form 4 | 15,000 | $558.9K | 2024-07-05 | SEC |
| 2024-08-07 | S, sale reported on Form 4 | 100 | $4.2K | 2024-08-09 | SEC |
| 2024-08-07 | S, sale reported on Form 4 | 7,667 | $318.3K | 2024-08-09 | SEC |
| 2024-08-07 | S, sale reported on Form 4 | 32,233 | $1.3M | 2024-08-09 | SEC |
| 2024-09-04 | S, sale reported on Form 4 | 25,641 | $1.2M | 2024-09-06 | SEC |
| 2024-09-04 | S, sale reported on Form 4 | 14,359 | $692.5K | 2024-09-06 | SEC |
| 2024-10-02 | S, sale reported on Form 4 | 30,288 | $1.7M | 2024-10-04 | SEC |
| 2024-10-02 | S, sale reported on Form 4 | 9,712 | $551.1K | 2024-10-04 | SEC |
| 2024-11-06 | S, sale reported on Form 4 | 14,000 | $828.4K | 2024-11-08 | SEC |
| 2024-11-06 | S, sale reported on Form 4 | 1,000 | $59.9K | 2024-11-08 | SEC |
| 2024-12-04 | S, sale reported on Form 4 | 1,672 | $78.9K | 2024-12-06 | SEC |
| 2024-12-04 | S, sale reported on Form 4 | 13,328 | $619.8K | 2024-12-06 | SEC |
| 2025-01-08 | S, sale reported on Form 4 | 12,132 | $591.1K | 2025-01-10 | SEC |
| 2025-01-08 | S, sale reported on Form 4 | 2,868 | $141.6K | 2025-01-10 | SEC |
| 2025-02-05 | S, sale reported on Form 4 | 15,000 | $608.7K | 2025-02-07 | SEC |
| 2025-03-05 | S, sale reported on Form 4 | 2,674 | $81.9K | 2025-03-07 | SEC |
| 2025-03-05 | S, sale reported on Form 4 | 7,326 | $219.6K | 2025-03-07 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 3,340 | $206.8K | 2025-11-13 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 14,774 | $932.8K | 2025-11-13 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 1,786 | $114.1K | 2025-11-13 | SEC |
| 2025-11-13 | S, sale reported on Form 4 | 100 | $6.5K | 2025-11-13 | SEC |
| 2025-12-04 | S, sale reported on Form 4 | 40,000 | $3.0M | 2025-12-05 | SEC |
| 2025-12-10 | S, sale reported on Form 4 | 9,435 | $706.5K | 2025-12-12 | SEC |
| 2025-12-10 | S, sale reported on Form 4 | 10,005 | $758.3K | 2025-12-12 | SEC |
| 2025-12-10 | S, sale reported on Form 4 | 560 | $42.9K | 2025-12-12 | SEC |
| 2026-01-14 | S, sale reported on Form 4 | 8,476 | $676.6K | 2026-01-16 | SEC |
| 2026-01-14 | S, sale reported on Form 4 | 2,374 | $192.3K | 2026-01-16 | SEC |
| 2026-01-14 | S, sale reported on Form 4 | 1,854 | $152.8K | 2026-01-16 | SEC |
| 2026-01-14 | S, sale reported on Form 4 | 470 | $39.4K | 2026-01-16 | SEC |
| 2026-01-14 | S, sale reported on Form 4 | 1,440 | $113.2K | 2026-01-16 | SEC |
| 2026-01-14 | S, sale reported on Form 4 | 5,386 | $447.9K | 2026-01-16 | SEC |
| 2026-02-11 | S, sale reported on Form 4 | 11,494 | $723.7K | 2026-02-13 | SEC |
| 2026-02-11 | S, sale reported on Form 4 | 955 | $62.1K | 2026-02-13 | SEC |
| 2026-02-11 | S, sale reported on Form 4 | 7,551 | $481.2K | 2026-02-13 | SEC |
| 2026-03-11 | S, sale reported on Form 4 | 3,418 | $259.3K | 2026-03-13 | SEC |
| 2026-03-11 | S, sale reported on Form 4 | 8,219 | $615.0K | 2026-03-13 | SEC |
| 2026-03-11 | S, sale reported on Form 4 | 8,363 | $621.3K | 2026-03-13 | SEC |
| 2026-04-08 | S, sale reported on Form 4 | 2,000 | $166.5K | 2026-04-10 | SEC |
| 2026-04-08 | S, sale reported on Form 4 | 200 | $17.0K | 2026-04-10 | SEC |
| 2026-04-08 | S, sale reported on Form 4 | 17,800 | $1.5M | 2026-04-10 | SEC |
| 2026-05-13 | S, sale reported on Form 4 | 18,659 | $1.5M | 2026-05-15 | SEC |
| 2026-05-13 | S, sale reported on Form 4 | 1,341 | $110.7K | 2026-05-15 | SEC |
| 2026-06-10 | S, sale reported on Form 4 | 7,654 | $633.6K | 2026-06-12 | SEC |
| 2026-06-10 | S, sale reported on Form 4 | 1,080 | $90.9K | 2026-06-12 | SEC |
| 2026-06-10 | S, sale reported on Form 4 | 6,770 | $556.6K | 2026-06-12 | SEC |
| 2026-06-10 | S, sale reported on Form 4 | 1,577 | $134.3K | 2026-06-12 | SEC |
| 2026-06-10 | S, sale reported on Form 4 | 2,305 | $198.9K | 2026-06-12 | SEC |
| 2026-06-10 | S, sale reported on Form 4 | 614 | $53.4K | 2026-06-12 | SEC |
| 2026-06-22 | S, sale reported on Form 4 | 80,000 | $10.6M | 2026-06-24 | SEC |
| 2026-07-08 | S, sale reported on Form 4 | 20,000 | $2.7M | 2026-07-10 | SEC |
Spyre Therapeutics, Inc. (SYRE)
Director · 7 filings · 5 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2026-05-08 | S, sale reported on Form 4 | 2,404 | $174.5K | 2026-05-08 | SEC |
| 2026-05-08 | S, sale reported on Form 4 | 24,814 | $1.9M | 2026-05-08 | SEC |
| 2026-05-08 | S, sale reported on Form 4 | 19,269 | $1.5M | 2026-05-08 | SEC |
| 2026-05-08 | S, sale reported on Form 4 | 33,513 | $2.5M | 2026-05-08 | SEC |
| 2026-06-22 | S, sale reported on Form 4 | 20,000 | $2.0M | 2026-06-23 | SEC |
ARYD
Director · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Source
Counted from the Form 4 filings this reporting owner (SEC CIK 1779990) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
